) release channels that are located on the sarcoplasmic reticulum (SR) membrane of virtually all mammalian cell types, including smooth muscle cells (SMC). Here, we have reviewed literature investigating IP 3R expression, cellular localization, tissue distribution, activity regulation, communication with ion channels and organelles, generation of Ca 2ϩ signals, modulation of physiological functions, and alterations in pathologies in SMCs. Three IP 3R isoforms have been identified, with relative expression and cellular localization of each contributing to signaling differences in diverse SMC types. Several endogenous ligands, kinases, proteins, and other modulators control SMC IP 3R channel activity. SMC IP3Rs communicate with nearby ryanodine-sensitive Ca 2ϩ channels and mitochondria to influence SR Ca 2ϩ release and reactive oxygen species generation. IP3R-mediated Ca 2ϩ release can stimulate plasma membrane-localized channels, including transient receptor potential (TRP) channels and store-operated Ca 2ϩ channels. SMC IP3Rs also signal to other proteins via SR Ca 2ϩ release-independent mechanisms through physical coupling to TRP channels and local communication with large-conductance Ca 2ϩ -activated potassium channels. IP 3R-mediated Ca 2ϩ release generates a wide variety of intracellular Ca 2ϩ signals, which vary with respect to frequency, amplitude, spatial, and temporal properties. IP 3R signaling controls multiple SMC functions, including contraction, gene expression, migration, and proliferation. IP 3R expression and cellular signaling are altered in several SMC diseases, notably asthma, atherosclerosis, diabetes, and hypertension. In summary, IP 3R-mediated pathways control diverse SMC physiological functions, with pathological alterations in IP 3R signaling contributing to disease. inositol 1,4,5-trisphosphate receptors; sarcoplasmic reticulum; calcium INTRACELLULAR CALCIUM (Ca 2ϩ ) signals are produced by both extracellular Ca 2ϩ influx and intracellular Ca 2ϩ release (22, 29). Ca 2ϩ influx can occur through plasma membrane ion channels and transporters, including voltage-dependent L-type Ca 2ϩ (Ca V 1.2) channels, nonselective cation channels, and the Na ϩ /Ca 2ϩ exchanger (22, 29) . Ca 2ϩ can also be released from intracellular stores, such as the sarcoplasmic reticulum (SR)/ endoplasmic reticulum (ER) and mitochondria (22, 29 ] i ) (13, 26, 90, 144, 158, 254) . These diverse Ca 2ϩ signals regulate physiological functions and are modified in diseases, leading to pathological consequences.
Many plasma membrane receptors couple via heteromeric G q/11 proteins to PLC (22, 29) . Upon agonist to receptor binding, PLC-catalyzed hydrolysis of phosphatidylinositol 4,5-bisphosphate generates diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP 3 ) (21, 57). IP 3 binds to and activates SR-localized IP 3 receptors (IP 3 Rs) (21, 57). SMC IP 3 Rs were first purified from aorta and, following reconstitution into phospholipid vesicles, were identified as Ca 2ϩ release channels (34, 52, 134). IP 3 Rs regulate many cellular processes in SMCs, including contractility, gene expression, migration, and proliferation (2, 60, 149, 156, 234, 237) .
The focus of this review is to discuss IP 3 R expression, cellular localization, channel activity, communication with ion channels and organelles, Ca 2ϩ signals generated, physiological functions regulated, and pathological alterations in SMCs. Excellent reviews have summarized knowledge gained from studies of recombinant IP 3 R channels and those expressed in a wide variety of different cell types (21, 57, 143, 171) . Here, IP 3 R signaling in non-SMC types will only be considered when extrapolation to SMCs is appropriate or when discussion may stimulate future research in SMCs.
IP 3 R Structure
IP 3 Rs are tetramers, with each subunit composed of three principal regions: an NH 2 terminus, a hydrophobic region comprising six transmembrane domains, and a COOH-terminal tail ( Fig. 1) (139, 246) . The cytosolic NH 2 -terminal region is functionally divided into the IP 3 -binding domain, a suppressor domain that inhibits IP 3 binding, and the regulatory domain ( Fig. 1, A and B) (57, 245) . The regulatory domain contains binding sites for ATP (Fig. 1A , red squares) and Ca 2ϩ (Fig. 1A , blue squares) and consensus sequences for phosphorylation (Fig. 1A , black squares) (57, 139, 171). A coupling domain through which IP 3 Rs physically interact with transient receptor potential canonical (TRPC) channels is also located in the regulatory domain (Fig. 1B) (2, 208) . The transmembrane domains anchor each IP 3 R subunit to the SR membrane (Fig. 1 , B and C) (139). The luminal loop between transmembrane domains 5 and 6 forms the Ca 2ϩ -permeable pore (Fig. 1B ) (139). The COOH-terminal tail extends from transmembrane domain 6 into the cytosol (Fig. 1, A and B) (139). The transmembrane domains and COOH-terminal tail appear to be essential for IP 3 R tetramerization (141, 188) .
IP 3 R Isoforms and Distribution in SMCs of Different Tissues
To date, three IP 3 R isoforms (IP 3 R1-3) have been identified, each of which is encoded by a different gene (57). Important features of mammalian IP 3 R isoforms are summarized in Table 1 . SMCs express all three IP 3 R isoforms, with relative levels of each determined by the tissue of origin and developmental stage. IP 3 R1 is the predominant isoform expressed in vascular SMCs (64, 84, 147, 228, 254, 257) . Quantitative PCR performed on isolated cerebral artery SMCs indicated that IP 3 R1 mRNA was the most abundant of the three isoforms, at 82% of total message, with much of the residual IP 3 R message being IP 3 R3 (254) . Similarly, IP 3 R1 was the major isoform detected in basilar and mesenteric arteries, whole thoracic aorta, cultured portal vein SMCs, and A7r5 cells, an aortic SMC line (64, 84, 147, 211, 228, 257) . Reports indicate that IP 3 R isoform expression in vascular SMCs shifts during ontogeny and proliferation (210, 211) . In neonatal (2-to 4-day-old) rats, IP 3 R1 protein was lower and IP 3 R3 protein was higher in SMCs of aorta and portal vein, compared with those in juvenile (6 wk-old) rats (210) . IP 3 R2 and IP 3 R3 levels were higher in proliferating, cultured aortic SMCs than in whole aorta homogenates (211) . IP 3 R isoform expression in nonvascular SMCs exhibits tissue variability. In isolated ureteric and myometrial SMCs, all three IP 3 R isoforms were detected (26, 148). IP 3 R3 was the predominant isoform, with IP 3 R1 and IP 3 R2 also present in tracheal SMCs (230) . In contrast, cultured ureteric and gastric SMCs expressed IP 3 R1 and IP 3 R3 but not IP 3 R2 (147, 154) . Tissue variability in IP 3 R isoform expression may contribute to signaling differences in these SMC types. 
Cellular Expression and Localization of SMC IP 3 Rs
Cellular levels of IP 3 Rs in SMCs are determined by an equilibrium between gene transcription and protein degradation (3, 129, 171, 227) . c-Myb, a transcription factor, binds to the IP 3 R1 promoter and stimulates transcription in cultured aortic SMCs (3) . In A7r5 cells, retinoic acid inhibited IP 3 R1 gene transcription through a mechanism mediated by activator protein-2, another transcription factor (45). In cultured aortic SMCs, hydrogen peroxide (H 2 O 2 ) stimulated proteasomal degradation of IP 3 R1 and IP 3 R3, whereas Jak2, a tyrosine kinase, phosphorylated IP 3 R1 and prevented proteasomal degradation (129, 227) . Transforming growth factor-␤ (TGF-␤) reduced IP 3 R1 and IP 3 R3 protein in renal arteriolar SMCs, although it was not determined if this was due to protein degradation (138). In A7r5 cells, vasopressin inhibited IP 3 R1 gene transcription and also stimulated protein degradation, suggesting that a physiological agonist can modulate SMC IP 3 R levels through both of these mechanisms (197) . Therefore, regulation of both gene transcription and protein degradation controls IP 3 R cellular levels in SMCs.
In SMCs, IP 3 Rs locate to the SR in different cellular regions, including central SR around the nucleus and peripheral SR beneath the plasma membrane (Table 1) (2, 26, 63, 162, 199, 211, 224, 254) . IP 3 R localization to central and/or peripheral SR is isoform and tissue dependent. In cerebral artery SMCs, IP 3 R1 distributes to both central and peripheral SR ( Fig. 2A ) (2, 254 3 Rs in close proximity to the plasma membrane, thereby permitting local signaling to membrane proteins, including ion channels (2, 255) . Therefore, IP 3 R cellular localization in SMCs likely contributes to distinct physiological functions regulated by these proteins.
IP 3 R Channel Properties in Vascular SMCs
Single channel properties of vascular SMC IP 3 Rs have been examined using purified aortic IP 3 Rs reconstituted into planar lipid bilayers (134). Reconstituted IP 3 Rs were found to be IP 3 -gated ion channels, most permeable to Ca 2ϩ , followed by K ϩ and Cl Ϫ (134). Bath application of 0.5 M IP 3 activated ϳ32-pS single channel currents after a delay of ϳ1 min in standard buffer with 50 mM Ca 2ϩ as the charge carrier ( Fig.  2B ) (134). The delayed response between bath application of IP 3 and stimulation of channel currents was suggested to be related to the diffusion of IP 3 in the bath (134). IP 3 -induced channel currents were enhanced by ATP (Fig. 2C ) and blocked by heparin (134).
The kinetics of IP 3 R-mediated Ca 2ϩ release in vascular SMCs have been investigated using permeabilized portal vein smooth muscle strips and flash photolysis of caged IP 3 (198) . Binding of IP 3 to a single IP 3 R subunit, as opposed to all four subunits of the tetramer, was sufficient to induce channel opening (198 (198) . Collectively, these studies (134, 198) provided important information regarding biophysical properties of IP 3 Rs and the kinetics of IP 3 R-mediated Ca 2ϩ release in vascular SMCs. (162, 199, 211) , A7r5 cells (224) Cultured aorta (199, 211) Cultured aorta (199, 211) Peripheral SR Cerebral artery (1, 2, 254) , cultured aorta (199, 211) , vas deferens (162), ileum (63)
Cultured aorta (199, 211) Cultured aorta (199, 211) 
Cellular Regulators of SMC IP 3 R Activity
This section will describe ligands, protein kinases, regulatory proteins, and other modulators that influence IP 3 R activity in SMCs. The reader is referred to earlier reviews (57, 127, 172, 213) where additional details of these and other IP 3 R regulators derived from reports in non-SMC types are discussed.
Ligands. Ligands that regulate SMC IP 3 R activity include IP 3 (195, 196) . One luminal and seven cytosolic Ca 2ϩ -binding sites (Fig. 1A , blue squares) have been identified on IP 3 Rs, suggesting that Ca 2ϩ binds to and directly influences IP 3 R activity (195, 196 3 Rs through more than one mechanism, although experimental evidence for such regulation is limited.
ATP binds to three sites located in the IP 3 R regulatory domain (Fig. 1A, black squares) . ATP is not required for SMC IP 3 R activation but enhances IP 3 and Ca 2ϩ sensitivity, thereby augmenting channel activity (77, 80, 134) . ATP alone did not stimulate aortic IP 3 Rs reconstituted into planar lipid bilayers but elevated IP 3 -induced currents (Fig. 2C) release-dependent and -independent mechanisms in SMCs. Evidence suggests that IP 3 R communication with these ion channels is enabled by caveolae, which are plasma membrane microdomains located between the SR and plasma membranes in many cell types, including SMCs (Fig. 3, A and B) . TRPC CHANNELS. IP 3 R activation stimulates TRPC channels directly, through physical coupling and indirectly, through Ca 2ϩ -dependent activation and induction of store-operated Ca 2ϩ entry (SOCE). Endothelin (ET)-1 and uridine 5=-triphosphate, PLC-coupled receptor agonists, and IP 3 stimulated physical coupling between the IP 3 R1 NH 2 -terminal TRPC coupling domain and the TRPC3 channel COOH-terminal CaM and IP 3 R binding (CIRB) domain in cerebral artery SMCs ( Fig.  3C ) (1, 2, 253) . In mammals, the TRPC coupling domain sequence (LϪϪϪϪϪϪEEVWLϪWϪD) and the CIRB domain sequence (YϪϪϪMKϪLVϪRYV) are conserved among the three IP 3 R isoforms and seven TRPC channels, respectively (208) . The IP 3 R coupling domain displaces inhibitory CaM from the TRPC CIRB domain, leading to channel activation (253) . Cerebral artery SMC TRPC6 channels also contain a CIRB domain but do not physically couple to IP 3 R1 due to spatial separation of these proteins (2) . IP 3 R1-induced TRPC3 channel activation induced a cation current (I Cat ), resulting in membrane depolarization, Ca V 1.2 channel activation, and vasoconstriction ( Fig. 3C) (237) . This SR-Ca 2ϩ release-independent mechanism is a major contributor to agonist-induced IP 3 R-mediated global [Ca 2ϩ ] i elevation and vasoconstriction in cerebral arteries (2, 237 release may feedback to stimulate SOCE, which exists in some but not all contractile and migratory/proliferative SMC types (5, 88, 97, 159, 185, 237, 239) . In addition to Orai and STIM proteins, TRP channels may be a molecular component of SOCE channels (73, 180, 229) . TRPC channels, including 1, 5, 6, and 7 contribute to SOCE in SMCs of coronary and mesenteric arteries and portal vein (186, 207) . IP 3 R-mediated SR Ca 2ϩ depletion activated TRPC-dependent SOCE in SMCs of inferior vena cava, portal vein, and pulmonary arteries (108, 114, 160, 180) .
SMC TRP channels are also activated by IP 3 R-independent mechanisms. TRPC channels, including 1, 3, 4, 5, 6, and 7 were activated by pathways that required PLC, phosphatidylinositol 4,5-bisphosphate, and/or DAG, but not IP 3 or IP 3 Rs, in SMCs of coronary, ear, and mesenteric arteries, portal vein, and gastric antrum (5, 6, 93, 109, 110, 174, 185) . Therefore, in SMCs, TRP channels are activated by PLC-mediated IP 3 Rdependent and -independent pathways. IP 3 R-dependent pathways include physical coupling with TRPC channels, Ca 2ϩ release-mediated activation, and SR Ca 2ϩ store depletioninduced stimulation.
BKCA CHANNELS. SMC IP 3 Rs communicate with nearby plasma membrane BK Ca channels via SR Ca 2ϩ release-dependent and -independent mechanisms (255) (Fig. 3D) 3 Rs, TRPC3, and BK Ca channels appear to be located in macromolecular complexes that span from the SR membrane to plasma membrane caveolae in SMCs. Caveolae disruption, knockdown of caveolin-1 (cav-1), a caveolae scaffolding protein, and a cav-1 scaffolding domain peptide spatially separated IP 3 R1 and TRPC3 channels and attenuated IP 3 -induced I Cat activation in cerebral artery SMCs (1, 47, 83) . Coimmunoprecipitation and immunofluorescence studies indicated that BK Ca channels associate with cav-1 in aortic and cerebral artery SMCs (7, 255) . Thus cav-1 likely maintains close spatial proximity of SR IP 3 R1 channels with both TRPC3 and BK Ca channels in SMCs (Fig. 3, C and D) (1, 7, 255) . Caveolae may permit localized coupling of IP 3 R1 to both TRPC3 and BK Ca channels to modulate SMC membrane potential and arterial contractility. Therefore, IP 3 Rs, TRPC3, and BK Ca channels appear to be located within the same cav-1-containing macromolecular complex that bridges the SR and plasma membrane in arterial SMCs (1, 255) . RyRs generate Ca 2ϩ sparks that activate nearby plasma membrane BK Ca channels in SMCs, inducing relaxation (90, 159). Given that SMC RyR channels can be located immediately (ϳ20 nm) beneath the plasma membrane (90), IP 3 Rs and RyRs may also be contained within the same macromolecular complexes and communicate locally to each other and nearby plasma membrane ion channels. Conceivably, SMC RyRs may communicate with TRP and BK Ca channels, thereby regulating membrane potential and contractility. Future research should be directed at exploring cellular localiza- Table 2 . Ca 2ϩ puffs. Ca 2ϩ puffs arise from the synchronous opening of ϳ30 IP 3 R channels distributed within a ϳ400-nm diameter cluster in Xenopus oocytes (170, 194 (10, 18, 29, 111, 190) . In isolated retinal arteriole SMCs, ET-1 increased Ca 2ϩ oscillation frequency and this elevation was inhibited by blockers of IP 3 Rs and RyRs, indicating that IP 3 R-RyR cross talk stimulates Ca 2ϩ oscillations (190, 218 (249) . Similarly, ANG II receptor antagonists abolished Ca 2ϩ ripples and reduced myogenic tone in tail arteries (9) . It was concluded that ANG II produced locally within the arterial wall stimulates Ca 2ϩ ripples, which regulate myogenic tone (9) . Therefore, IP 3 Rmediated Ca 2ϩ ripples may be a Ca 2ϩ signal by which the local renin-angiotensin system in the arterial wall contributes to myogenic constriction (9, 249 sparks, albeit in a small number of SMC types (116, 190, 218, 252) . RyR-and IP 3 R-mediated SR Ca 2ϩ release both stimulated Ca 2ϩ sparks in SMCs of choroidal and retinal arterioles, pulmonary artery, and trachea (116, 190, 218, 252) . In contrast, IP 3 R inhibition elevated Ca 2ϩ spark frequency in vas deferens SMCs, although this may have occurred due to an [Ca 2ϩ ] SR elevation (233) . Reports (190, 218) ] i could be due to multiple factors, including differences in the amplitude of Ca 2ϩ signals generated, activation and contribution of other Ca 2ϩ channels, and regulation of IP 3 R activity by tissue-specific proteins. In summary, IP 3 R activation, sometimes with the involvement of other Ca 2ϩ channels, produces a wide variety of intracellular Ca 2ϩ signals, which control several physiological functions in SMCs.
IP 3 R Regulation of SMC Physiological Functions
IP 3 Rs regulate SMC physiological functions, including contractility, gene expression, migration, and proliferation ( Table  2) . IP 3 R control of these functions can occur via the modulation of intracellular Ca 2ϩ signals and via local communication with ion channels and organelles.
Contractility. IP 3 R-mediated SR Ca 2ϩ release stimulates contraction in both vascular and nonvascular SMCs. In gallbladder SMCs, IP 3 R activation contributed to Ca 2ϩ flashes and action potentials that preceded rhythmic contractions of individual smooth muscle bundles (13) . IP 3 R-mediated Ca 2ϩ oscillations induced airway and basilar artery contraction (10, 18, 67) . Ca 2ϩ sparks generated by IP 3 R and RyR activation contributed to vasoconstriction in retinal and choroidal arterioles (190, 218) . Reports in mesenteric, pulmonary, and tail arteries, inferior vena cava, and portal vein proposed that IP 3 R-mediated Ca 2ϩ waves directly induce vasoconstriction (28, 42, 49, 76, 86, 104, 107, 108, 133, 184, 249). XeC inhibited agonistinduced contraction in iliac lymph vessels, pulmonary arteries, and small femoral artery branches, indicating that agonists induce vasoconstriction through IP 3 R activation (87, 99, 121, 128, 235) . Similarly, in nonvascular SMCs of ileum, prostate, small intestine, and trachea, IP 3 R blockers inhibited spontaneous and agonist-induced contraction (54, 103, 122, 167) . In airway and intestinal SMCs, membrane depolarization activated IP 3 Rs and RyRs, which contributed to contraction (17, 70, 96, 115) . Collectively, IP 3 R-mediated Ca 2ϩ release regulates spontaneous and agonist-induced contraction of vascular and nonvascular SMCs. IP 3 R activation and the resulting SR Ca 2ϩ store depletion also stimulated SOCE channel-dependent Ca 2ϩ influx, which induced contraction of SMCs of aorta, inferior vena cava, cremaster, and pulmonary arteries (107, 108, 160, 177, 220, 250) . IP 3 R activation has also been reported to induce relaxation of certain SMC types (15, 102) . In colonic SMCs, IP 3 R-mediated Ca 2ϩ release stimulated K Ca channels, resulting in spontaneous transient outward currents, hyperpolarization, and relaxation (15, 102) . However, in urinary bladder SMCs, electrical field stimulation enhanced Ca 2ϩ waves, which did not induce contraction (157) , suggesting that IP 3 Rs do not control contractility in certain SMC types.
IP 3 R regulation of pressure-induced myogenic vasoconstriction has been examined in several vascular beds. U-73122, a PLC inhibitor, dilated pressurized cerebral and ophthalmic arteries, suggesting that DAG/PKC and/or IP 3 /IP 3 Rs contribute to myogenic tone (85, 92, 166, 237) . Inhibitors of PLC or IP 3 Rs attenuated Ca 2ϩ waves and dilated pressurized cremaster muscle feed arteries and arterioles, suggesting that IP 3 R-de-pendent Ca 2ϩ waves regulate myogenic tone in these vessels (231) . Similarly, in pressurized mesenteric and tail arteries, IP 3 R-mediated Ca 2ϩ ripples were proposed to stimulate myogenic constriction (9, 249) . SR-dependent Ca 2ϩ waves contributed to myogenic tone at low intravascular pressure in cerebral artery SMCs, although the contribution of IP 3 Rs was not determined (151) . These studies suggest that IP 3 R-mediated Ca 2ϩ release regulates the myogenic response. In contrast, in pressurized mesenteric and cerebral arteries, IP 3 R-dependent Ca 2ϩ oscillations and waves did not contribute significantly to myogenic vasoconstriction (88, 144, 254). Explanations for these different observations include that the frequency and amplitude of IP 3 R-mediated Ca 2ϩ signals are likely to be important factors that determine functional impact on contractility. In addition, the activation status of other signaling pathways that may enhance the sensitivity of the contractile apparatus to IP 3 R-induced Ca 2ϩ release is also likely to modify functional responses.
IP 3 Rs also control arterial SMC contractility via an SR Ca 2ϩ release-independent mechanism that involves physical coupling to plasma membrane TRPC3 channels (Fig. 3C) (1, 2, 237, 254). In cerebral arteries at physiological intravascular pressure, the majority (ϳ60%) of IP 3 -induced vasoconstriction occurred through IP 3 R1-TRPC3 physical coupling, with a minor contribution from IP 3 R-mediated SR Ca 2ϩ release (237) . At low intravascular pressure, where [Ca 2ϩ ] SR is low and the driving force for cation influx is high, IP 3 R1-TRPC3 physical coupling fully accounted for IP 3 -induced vasoconstriction (237) . Thus, in cerebral artery SMCs, IP 3 Rs induce contraction primarily via an SR Ca 2ϩ release-independent mechanism that involves TRPC3 channel activation. In summary, SMC contractility regulation by IP 3 Rs appears to be tissue and stimulus dependent. Contrary to what was previously a prevailing view, IP 3 R-mediated Ca 2ϩ release induces contraction in some, but not all, SMC types, with IP 3 R activation also stimulating contraction via SR Ca 2ϩ release-independent mechanisms.
Gene expression. IP 3 R-mediated Ca 2ϩ release can activate transcription factors, thereby regulating gene expression in SMCs (40, 51, 60, 156). In cerebral artery SMCs, IP 3 Rmediated SR Ca 2ϩ release activated NF-B both directly and indirectly, by stimulating mitochondrial ROS production (Fig.  4B) (156) . IP 3 R-dependent NF-B activation stimulated Ca V 1.2 channel ␣ 1C subunit gene expression, leading to vasoconstriction (156) . NF-B p105/p50 subunit expression was also upregulated by IP 3 R-mediated SR Ca 2ϩ release via a mitochondrial ROS-and NF-B-independent pathway (156) . In cerebral artery and cultured aortic SMCs, IP 3 R-dependent SR Ca 2ϩ release stimulated nuclear factor of activated T-cell c3, a transcription factor that can downregulate K Ca channel ␤1-subunit and Kv2.1 channel expression (8, 60, 113, 161 20, 149, 205, 228, 234 ). Proliferation correlated with an elevation in IP 3 R1 expression in aortic and carotid artery SMCs and upregulation of all three IP 3 R isoforms in mesenteric artery SMCs (3, 20) . Consistent with these observations, Ca 2ϩ wave frequency was elevated in proliferating cerebral artery SMCs (234) . PLC and IP 3 R antagonists attenuated Ca 2ϩ waves and proliferation in cerebral artery SMCs, indicating that IP 3 Rmediated Ca 2ϩ release stimulates proliferation (234) . Similarly, in cultured aortic SMCs, IP 3 R-dependent intercellular Ca 2ϩ waves promoted proliferation and migration (149). An elevation in IP 3 R-mediated Ca 2ϩ release also stimulated proliferation of cultured preglomerular microvascular SMCs (36). XeC inhibited pulsatile pressure-induced aortic SMC migration, and IP 3 R1 knockdown reduced A7r5 cell proliferation (205, 228) . Taken together, these findings provide strong evidence that IP 3 R activation stimulates SMC migration and proliferation.
IP 3 Rs and SMC Pathologies
Vascular SMC diseases. Vascular SMC IP 3 R expression, [IP 3 ] i , and Ca 2ϩ signaling are altered in several diseases, including hypertension, atherosclerosis, and diabetes-related vascular complications (19, 125, 130, 138, 192, 193, 236) . During the pathogenesis of atherosclerosis, vascular SMCs are exposed to oxidized LDL, which stimulates plaque formation (130). In aortic SMCs exposed to oxidized LDL and in atherosclerotic aorta, IP 3 R1 protein and IP 3 R-dependent Ca 2ϩ release were reduced (125, 130) . SERCA2b expression was also downregulated in atherosclerotic aorta, suggesting that an [Ca 2ϩ ] SR reduction may also contribute to the impaired IP 3 Rmediated Ca 2ϩ release in atherosclerosis (125, 130) . Diabetes-related vascular complications are associated with a reduction in IP 3 R expression and Ca 2ϩ release in SMCs of aorta and glomerular arterioles (138, 192, 193) . In renal glomerular arteriolar SMCs of diabetic rats, IP 3 R protein was lower than in nondiabetic controls (138). Protein expression of all three IP 3 R isoforms and IP 3 R-mediated [Ca 2ϩ ] i signals were attenuated in aortic SMCs of genetic and inducible animal models of diabetes (192) . High glucose reduced IP 3 R protein in A7r5 cells, suggesting that a diabetes-induced reduction in vascular SMC IP 3 R levels may be due to direct effects of hyperglycemia (192) . IP 3 R1 protein and IP 3 R-mediated [Ca 2ϩ ] i elevations were reduced, and TGF-␤ 2 levels were elevated in diabetic rat aorta (193) . Intraperitoneal administration of an anti-TGF-␤ antibody partly restored IP 3 R1 expression and IP 3 R-mediated [Ca 2ϩ ] i elevations in aortic and glomerular arteriolar SMCs and prevented the development of glomerular hypertrophy (138, 193) . These reports suggested that TGF-␤-induced suppression of IP 3 R expression underlies vascular dysfunction, leading to diabetic glomerular hypertrophy. Collectively, these studies indicate that an alteration in IP 3 R expression and IP 3 R-mediated Ca 2ϩ signaling in vascular SMCs contributes to the pathogenesis of vascular diseases.
Asthma. Asthma is associated with enhanced SMC [IP 3 ] i , IP 3 R signaling, and contractility, leading to airway hyperresponsiveness and remodeling (132, 209) . In Fisher rats, an asthmatic animal model, IP 3 -5-phosphatase expression and activity were both reduced, leading to elevations in [IP 3 ] i and IP 3 R-mediated Ca 2ϩ release in airway SMCs (209) . This enhanced IP 3 -induced Ca 2ϩ release may underlie airway SMC hyperresponsiveness in asthma (209) . 2-Aminoethoxydiphenyl borate inhibited acidic pH-induced remodeling of airway SMCs, suggesting that IP 3 Rs may also regulate extracellular matrix formation and airway remodeling in asthma (132).
Pathologies associated with IP 3 R gene deletion and mutation. Studies performed in IP 3 R knockout (IP 3 R Ϫ/Ϫ ) mice have provided valuable information regarding pathologies associated with these proteins, although limited information is available regarding SMC dysfunction. IP 3 R1
Ϫ/Ϫ mice are rarely born alive, indicating that IP 3 R1 is crucial for embryonic development (131). Animals that survive exhibit severe neurological pathologies, including ataxia and epilepsy (131). IP 3 R1
ϩ/Ϫ mice displayed increased susceptibility to glucose intolerance, insulin resistance, and diet-induced diabetes (243) . A report (200) that examined SMC function in IP 3 R1
Ϫ/Ϫ mice determined that gastric SMCs exhibited irregular bursts of spike potentials, resulting in reduced contractility.
Population analysis studies have identified human diseases caused by IP 3 R gene mutations. Similar to observations in knockout mice, there is a strong correlation between IP 3 R gene mutations and neurological disease. A heterozygous deletion and a mutation in the IP 3 R1 gene have been identified in patients with spinocerebellar ataxia and tremors (68, 221) . SMC pathologies have not been reported that are associated with deletions or mutations in IP 3 R genes. Recent studies (75, 165) reported that single nucleotide polymorphisms in genes encoding IP 3 R3 and IP 3 3-kinase C, which phosphorylates IP 3 to IP 4 , predisposed children with Kawasaki disease, a pediatric systemic vascular autoimmune disease, to coronary artery aneurysms.
Summary
Since the discovery of IP 3 Rs more than 20 years ago, research has identified these proteins as SR-located ion channels that are expressed in virtually all cell types. In SMCs, IP 3 R signaling pathways and mechanisms involved are diverse (Fig.  6) . IP 3 R isoforms, cellular expression, and localization influence channel functions (Fig. 6A) . Several endogenous ligands, kinases, and proteins regulate SMC IP 3 R activity (Fig. 6B) . IP 3 R signaling involves communication with cellular organelles, including mitochondria, RyRs, and plasma membrane ion channels in SMCs (Fig. 6C) . IP 3 R-mediated cellular pathways include both SR Ca 2ϩ release-dependent and -independent mechanisms regulated through physical coupling to ion channels and control of SOCE. IP 3 R-mediated Ca 2ϩ release generates a wide variety of local and global Ca 2ϩ signals in SMCs (Fig. 6D) . IP 3 R-dependent cellular mechanisms control SMC physiological functions, including contraction, gene expression, migration, and proliferation (Fig. 6E) . Diseases of SMC-containing tissues are associated with altered IP 3 R expression and channel activity. Thus IP 3 Rs control SMC physiological functions and pathological alterations in IP 3 R signaling contribute to disease.
Future Directions
This review has summarized studies investigating IP 3 R expression, cellular localization, activity, Ca 2ϩ signals generated, physiological functions regulated, and associated pathologies in SMCs. There are still major questions that remain regarding IP 3 R functionality in SMCs. Studies are necessary to better determine mechanisms that regulate IP 3 R gene transcription and protein expression in SMCs. IP 3 R signaling in non-SMCs is modulated by a wide variety of proteins, including calmodulin, Ca 2ϩ -binding protein 1, Ca 2ϩ -and integrin-binding protein 1, chromogranins, ERp44, IP 3 R-binding protein released with IP 3 , and G␤␥ (57, 212). Modulation of IP 3 R signaling by these proteins should be examined in SMCs. Studies should also be aimed at determining other cellular organelles and ion channels that interact with IP 3 Rs in SMCs. A better understanding of the contribution of RyRs and other Ca 2ϩ channels to IP 3 R-mediated Ca 2ϩ signals in SMCs is also needed. Research is required to elucidate mechanisms that underlie tissuespecific variability in IP 3 R signaling in SMCs. Studies would benefit from the availability of novel, selective, high-affinity, membrane-permeant IP 3 R antagonists to investigate IP 3 R signaling, physiological functions, and pathological alterations. SMC-specific IP 3 R animal models, including those that induce knockout, express IP 3 R mutations associated with human diseases, or alter known IP 3 R coupling domains, would also provide the capability to investigate the contribution of these proteins to physiological functions and pathological alterations both in vivo and in vitro. SMC dysfunctions in IP 3 R knockout mice also need to be examined. Screening of humans to identify potential IP 3 R mutations associated with SMC diseases is also necessary.
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